Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia

International Journal of Cardiology

Volumn 170, Issue 2 SUPPL.1, 2013, Pages

  Pirillo, Angela ^a,b   Catapano, Alberico Luigi ^b  

^a Bassini Hospital   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Diabetes; Docosahexaenoic acid; Eicosapentaenoic acid; Hypertriglyceridaemia; Omega 3 fatty acids; Triglyceride

Indexed keywords

ATORVASTATIN; DOCOSAHEXAENOIC ACID; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; NICOTINIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERTRIGLYCERIDEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

DIABETES; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; HYPERTRIGLYCERIDAEMIA; OMEGA-3 FATTY ACIDS; TRIGLYCERIDE;

ANIMALS; FATTY ACIDS, OMEGA-3; HUMANS; HYPERTRIGLYCERIDEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84890139178     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.06.040     Document Type: Article

References (59)

1. B.G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308 (Pubitemid 47080484)
2. J.J. Freiberg, A. Tybjaerg-Hansen, J.S. Jensen, and B.G. Nordestgaard Nonfasting triglycerides and risk of ischemic stroke in the general population JAMA 300 2008 2142 2152
3. J. Labreuche, P.J. Touboul, and P. Amarenco Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies Atherosclerosis 203 2009 331 345
4. A. Morrison, and J.E. Hokanson The independent relationship between triglycerides and coronary heart disease Vasc Health Risk Manag 5 2009 89 95
5. N. Sarwar, J. Danesh, and G. Eiriksdottir Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458 (Pubitemid 46184196)
6. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219 (Pubitemid 26266496)
7. A. Varbo, M. Benn, A. Tybjaerg-Hansen, A.B. Jorgensen, R. Frikke-Schmidt, and B.G. Nordestgaard Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 2013 427 436
8. E. Di Angelantonio, N. Sarwar, and P. Perry Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
9. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
10. M. Miller, N.J. Stone, and C. Ballantyne Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
11. A.L. Catapano, Z. Reiner, and G. De Backer ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
12. P.M. Kris-Etherton, W.S. Harris, and L.J. Appel Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 106 2002 2747 2757 (Pubitemid 35364932)
13. T.A. Jacobson, S.B. Glickstein, J.D. Rowe, and P.N. Soni Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review J Clin Lipidol 6 2012 5 18
14. W.S. Harris, H.N. Ginsberg, and N. Arunakul Safety and efficacy of Omacor in severe hypertriglyceridemia J Cardiovasc Risk 4 1997 385 391 (Pubitemid 28078682)
15. K. Musa-Veloso, M.A. Binns, and A.C. Kocenas Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides Nutr Rev 68 2010 155 167
16. T.A. Jacobson Role of n - 3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease Am J Clin Nutr 87 2008 1981S 1990S (Pubitemid 351872679)
17. D.C. Chan, G.F. Watts, P.H. Barrett, L.J. Beilin, T.G. Redgrave, and T.A. Mori Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia Diabetes 51 2002 2377 2386 (Pubitemid 34827385)
18. E.J. Chan, and L. Cho What can we expect from omega-3 fatty acids? Cleve Clin J Med 76 2009 245 251
19. H.J. Pownall, D. Brauchi, and C. Kilinc Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins Atherosclerosis 143 1999 285 297 (Pubitemid 29166909)
20. K.C. Maki, A.L. Lawless, and K.M. Kelley Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia J Cardiovasc Pharmacol 57 2011 489 494
21. R.J. Woodman, T.A. Mori, and V. Burke Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients Diabetes Care 26 2003 253 (Pubitemid 36929035)
22. K.C. Maki, B.C. Lubin, M.S. Reeves, M.R. Dicklin, and W.S. Harris Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia J Clin Lipidol 3 2009 33 38
23. M.H. Davidson, E.A. Stein, and H.E. Bays Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 29 2007 1354 1367 (Pubitemid 47348116)
24. H.E. Bays, J. McKenney, K.C. Maki, R.T. Doyle, R.N. Carter, and E. Stein Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin Mayo Clin Proc 85 2010 122 128
25. H.E. Bays, A.P. Tighe, R. Sadovsky, and M.H. Davidson Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications Expert Rev Cardiovasc Ther 6 2008 391 409
26. E.M. Roth, H.E. Bays, and A.D. Forker Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects J Cardiovasc Pharmacol 54 2009 196 203
27. G.C. Shearer, J.V. Pottala, S.N. Hansen, V. Brandenburg, and W.S. Harris Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial J Lipid Res 53 2012 2429 2435
28. H.E. Bays, C.M. Ballantyne, J.J. Kastelein, J.L. Isaacsohn, R.A. Braeckman, and P.N. Soni Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial) Am J Cardiol 108 2011 682 690
29. C.M. Ballantyne, H.E. Bays, and J.J. Kastelein Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study) Am J Cardiol 110 2012 984 992
30. T. Mazzone, A. Chait, and J. Plutzky Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies Lancet 371 2008 1800 1809 (Pubitemid 351697956)
31. P.M. Kearney, L. Blackwell, and R. Collins Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
32. J. Hartweg, A.J. Farmer, R. Perera, R.R. Holman, and H.A. Neil Meta-analysis of the effects of n - 3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes Diabetologia 50 2007 1593 1602 (Pubitemid 47036644)
33. K.E. Friday, M.T. Childs, C.H. Tsunehara, W.Y. Fujimoto, E.L. Bierman, and J.W. Ensinck Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes Diabetes Care 12 1989 276 281 (Pubitemid 19092238)
34. M. Borkman, D.J. Chisholm, and S.M. Furler Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM Diabetes 38 1989 1314 1319 (Pubitemid 19247429)
35. R.J. Woodman, T.A. Mori, V. Burke, I.B. Puddey, G.F. Watts, and L.J. Beilin Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension Am J Clin Nutr 76 2002 1007 1015 (Pubitemid 35244671)
36. H. Glauber, P. Wallace, K. Griver, and G. Brechtel Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus Ann Intern Med 108 1988 663 668
37. S.E. Kasim, B. Stern, S. Khilnani, P. McLin, S. Baciorowski, and K.L. Jen Effects of omega-3 fish oils on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients J Clin Endocrinol Metab 67 1988 1 5
38. I.L. Mostad, K.S. Bjerve, S. Lydersen, and V. Grill Effects of marine n - 3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes Eur J Clin Nutr 62 2008 419 429 (Pubitemid 351356583)
39. J. Hartweg, R. Perera, V. Montori, S. Dinneen, H.A. Neil, and A. Farmer Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus Cochrane Database Syst Rev 20 1 2008 CD003205
40. V.M. Montori, A. Farmer, P.C. Wollan, and S.F. Dinneen Fish oil supplementation in type 2 diabetes: a quantitative systematic review Diabetes Care 23 2000 1407 1415
41. C.E. Friedberg, M.J. Janssen, R.J. Heine, and D.E. Grobbee Fish oil and glycemic control in diabetes. A meta-analysis Diabetes Care 21 1998 494 500 (Pubitemid 28172922)
42. J. Hartweg, A.J. Farmer, R.R. Holman, and A. Neil Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes Curr Opin Lipidol 20 2009 30 38
43. P. Kazemian, S.M. Kazemi-Bajestani, A. Alherbish, J. Steed, and G.Y. Oudit The use of omega-3 poly-unsaturated fatty acids in heart failure: a preferential role in patients with diabetes Cardiovasc Drugs Ther 26 2012 311 320
44. C.D. Poole, J.P. Halcox, and S. Jenkins-Jones Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study Clin Ther 35 2013 40 51
45. F.B. Hu, E. Cho, K.M. Rexrode, C.M. Albert, and J.E. Manson Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women Circulation 107 2003 1852 1857 (Pubitemid 36444124)
46. D. Kromhout, J.M. Geleijnse, and J. de Goede n - 3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes Diabetes Care 34 2011 2515 2520
47. J. Bosch, H.C. Gerstein, and G.R. Dagenais n - 3 fatty acids and cardiovascular outcomes in patients with dysglycemia N Engl J Med 367 2012 309 318
48. M. Kaushik, D. Mozaffarian, D. Spiegelman, J.E. Manson, W.C. Willett, and F.B. Hu Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus Am J Clin Nutr 90 2009 613 620
49. Y. Zhou, C. Tian, and C. Jia Association of fish and n - 3 fatty acid intake with the risk of type 2 diabetes: a meta-analysis of prospective studies Br J Nutr 108 2012 408 417
50. J.H. Wu, R. Micha, and F. Imamura Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis Br J Nutr 107 Suppl. 2 2012 S214 S227
51. R. Giacco, V. Cuomo, and B. Vessby Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of n - 6 and n - 3 fatty acids? Nutr Metab Cardiovasc Dis 17 2007 572 580 (Pubitemid 47302305)
52. W.S. Harris n - 3 fatty acids and serum lipoproteins: human studies Am J Clin Nutr 65 5 Suppl. 1997 1645S 1654S (Pubitemid 27187958)
53. C.J. Glueck, N. Khan, M. Riaz, J. Padda, Z. Khan, and P. Wang Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels > 500 mg/dl despite conventional triglyceride lowering therapy Lipids Health Dis 11 2012 143
54. N. Svaneborg, J.M. Møller, E.B. Schmidt, K. Varming, H.H. Lervang, and J. Dyerberg The acute effects of a single very high dose of n - 3 fatty acids on plasma lipids and lipoproteins in healthy subjects Lipids 29 1994 145 147 (Pubitemid 24073051)
55. W.S. Harris, D.W. Rothrock, and A. Fanning Fish oils in hypertriglyceridemia: a dose-response study Am J Clin Nutr 51 1990 399 406
56. G. Schectman, S. Kaul, G.D. Cherayil, M. Lee, and A. Kissebah Can the hypotriglyceridemic effect of fish oil concentrate be sustained? Ann Intern Med 110 1989 346 352 (Pubitemid 19073650)
57. G.D. Norata, S. Raselli, and L. Grigore Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells Atherosclerosis 206 2009 556 562
58. G.D. Norata, and A.L. Catapano Triglyceride-rich lipoproteins from normotrygliceridemic subjects and hyperlipidemic patients differently affect endothelial cell activation and gene expression patterns Circ Res 100 2007 e81
59. G.D. Norata, L. Grigore, and S. Raselli Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies Atherosclerosis 193 2007 321 327 (Pubitemid 47064402)